Florence Duffaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Florence Duffaud has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
A. Le Cesne
15 shared publications- Jean-Yves Blay
Medical Oncology Department Centre Léon Bérard Lyon France
14 shared publications M. Rios
11 shared publications- Emmanuelle Bompas
Department of Medical Oncology, Institute de Cancérologie de l’Ouest, Saint-Herblain, France
10 shared publications F. Bertucci
10 shared publicationsN. Isambert
10 shared publications
Latest Publications
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi483
The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment
Background: Since 2009 a network of 26 reference centres for sarcoma patients (pts) in France was designated by the French National Cancer Institute. The outcome of the 26,883 pts discussed in these 26 NETSARC multidisciplinary tumour boards (NMTB) is presented.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi483
The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment
Background: Since 2009 a network of 26 reference centres for sarcoma patients (pts) in France was designated by the French National Cancer Institute. The outcome of the 26,883 pts discussed in these 26 NETSARC multidisciplinary tumour boards (NMTB) is presented.
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S688
3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc)
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51, S688
3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc)
- Open Access
- 12 May 2015
- Published by H1 Connect in F1000Prime Reports
- Vol. 7 (55) , 55
Recent advances in understanding and managing leiomyosarcomas
Recent advances in understanding and managing leiomyosarcomas
- 12 May 2015
- Published by H1 Connect in F1000Prime Reports
- Vol. 7 (55) , 55
Open AccessRecent advances in understanding and managing leiomyosarcomas
Recent advances in understanding and managing leiomyosarcomas
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S666-S667
9413 POSTER Primary Localized Gastrointestinal Stromal Tumours (GIST) of the Duodenum – a French Sarcoma Group (FSG) Retrospective Review of 84 Patients (pts)
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S666-S667
9413 POSTER Primary Localized Gastrointestinal Stromal Tumours (GIST) of the Duodenum – a French Sarcoma Group (FSG) Retrospective Review of 84 Patients (pts)
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e20506
Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
E20506 Background: The aim of this work was to investigate factors predicting progression-free survival (PFS) and overall survival (OS) of patients (pts) with advanced GIST treated with 400 mg/day IM included in the BFR14 study. Methods: 434 pts were included in this prospective multicenter trial from June 2002 to July 2009. After 1, 3 and 5 yrs of IM 400mg/day, pts free from progression were randomly offered to continue or interrupt (I arm) IM. Pts allocated to the I arm could restart IM (same dose) in case of progression. Pts declining randomization proceed with IM. Since time to secondary resistance to IM and OS were similar in both arms, prognostic factors for survival were therefore investigated in the entire cohort (randomized and not randomized pts) included in the BFR14. Survival was defined from the date of inclusion to the date of death for OS or to the first occurrence of progression or death for PFS. Baseline characteristics were tested in a univariate step. Variables statistically significant at 0.10 alpha-level were included in a multivariate Cox model. A backward stepwise procedure was used to identify independent prognostic factors for PFS then OS. Results: As of January 2011, after a median follow-up of 41.7 months (CI95% = [35.2 – 48.4]), there were 254 events (58.5%) and 134 deaths (30.9%). The 2 and 3-yrs PFS were 52% and 42% respectively. PS 0, normal platelets count and CD34-positivity on tumor cells were the three independent prognostic factors of a higher PFS. The 2 and 3-yrs OS were 83% and 73% respectively. A higher OS was independently predicted by sex (female), PS (0), platelets count (1,500/mm3). Mutational analysis is ongoing. Conclusions: In this large series of advanced GIST pts treated with standard dose IM, pts with a good PS and normal platelet counts have a favourable outcome, both on PFS and OS. GIST expressing CD34 have a better PFS. Male GIST pts and pts with lymphopenia have a dismal OS.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e20506
Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.
E20506 Background: The aim of this work was to investigate factors predicting progression-free survival (PFS) and overall survival (OS) of patients (pts) with advanced GIST treated with 400 mg/day IM included in the BFR14 study. Methods: 434 pts were included in this prospective multicenter trial from June 2002 to July 2009. After 1, 3 and 5 yrs of IM 400mg/day, pts free from progression were randomly offered to continue or interrupt (I arm) IM. Pts allocated to the I arm could restart IM (same dose) in case of progression. Pts declining randomization proceed with IM. Since time to secondary resistance to IM and OS were similar in both arms, prognostic factors for survival were therefore investigated in the entire cohort (randomized and not randomized pts) included in the BFR14. Survival was defined from the date of inclusion to the date of death for OS or to the first occurrence of progression or death for PFS. Baseline characteristics were tested in a univariate step. Variables statistically significant at 0.10 alpha-level were included in a multivariate Cox model. A backward stepwise procedure was used to identify independent prognostic factors for PFS then OS. Results: As of January 2011, after a median follow-up of 41.7 months (CI95% = [35.2 – 48.4]), there were 254 events (58.5%) and 134 deaths (30.9%). The 2 and 3-yrs PFS were 52% and 42% respectively. PS 0, normal platelets count and CD34-positivity on tumor cells were the three independent prognostic factors of a higher PFS. The 2 and 3-yrs OS were 83% and 73% respectively. A higher OS was independently predicted by sex (female), PS (0), platelets count (1,500/mm3). Mutational analysis is ongoing. Conclusions: In this large series of advanced GIST pts treated with standard dose IM, pts with a good PS and normal platelet counts have a favourable outcome, both on PFS and OS. GIST expressing CD34 have a better PFS. Male GIST pts and pts with lymphopenia have a dismal OS.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10093
Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG).
10093 Background: PCS are very rare tumors with poor prognosis. The current study aimed to evaluate clinico-pathological characteristics, treatment and survival in a cohort of patients (pts) referred to the FSG Network. Methods: From June 1977 to January 2010, 123 pts with PCS were identified. Medical records and clinicopathologic data were collected. Results: There were 54 men (44%) and 69 females (56%) with a median age of 47 years (range 3-82). Median time between first symptoms and diagnosis was 1 months (mo) (range 0-53). The most frequent revealing clinical signs were dyspnea (41%), thoracic pain (22%), heart failure (13%) and pericarditis (5%). The median tumor size was 60 mm (range 8-100). The pathological diagnoses included poorly differentiated sarcoma (S) (n=45), angioS (n=40), leiomyoS (n=16), synovialoS (n=7), rhabdomyoS (n=6), Ewing S (n=4), lipoS (n=3) and chondroS (n=2). At diagnosis, 99 pts (80%) had a localized disease and 24 pts had metastases in one site (n=14) or in multiple sites (n=10). The most frequent metastatic sites were lung (n=9), liver (n=7), bone (n=7), brain (n=4). Tumors were mainly located in the atrial cavities (right atrium n=47; left atrium n=44). Other localization included right ventricle (n= 6), left ventricle (n=9) and pericardium (n=3). In 11 cases, the tumor was multifocal. A surgical approach was considered in the majority of pts with localized disease. Resection alone or in combination with doxorubicin-containing chemotherapy (CT) or with a radiotherapy and CT regimen was undertaken in 18, 43 and 16 pts respectively. Among these pts, surgical approaches included wide excision (n=10), marginal excision (n=22), intralesional excision (n=31) and heart transplant (n=5). The median follow up was 13 mo (0-153), the median overall survival (OS) for those who underwent R0 excision was 39 mo (range 8-96) versus 17 mo (range 0-153) for those with R1 or R2 resection. The median OS of pts with initial metastatic disease treated with doxorubicin-containing CT was 11 mo (range 2-95). Conclusions: Complete surgical excision is associated with long-term survival. However, the poor prognosis of this malignancy requires extensive multidisciplinary research studies.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10093
Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG).
10093 Background: PCS are very rare tumors with poor prognosis. The current study aimed to evaluate clinico-pathological characteristics, treatment and survival in a cohort of patients (pts) referred to the FSG Network. Methods: From June 1977 to January 2010, 123 pts with PCS were identified. Medical records and clinicopathologic data were collected. Results: There were 54 men (44%) and 69 females (56%) with a median age of 47 years (range 3-82). Median time between first symptoms and diagnosis was 1 months (mo) (range 0-53). The most frequent revealing clinical signs were dyspnea (41%), thoracic pain (22%), heart failure (13%) and pericarditis (5%). The median tumor size was 60 mm (range 8-100). The pathological diagnoses included poorly differentiated sarcoma (S) (n=45), angioS (n=40), leiomyoS (n=16), synovialoS (n=7), rhabdomyoS (n=6), Ewing S (n=4), lipoS (n=3) and chondroS (n=2). At diagnosis, 99 pts (80%) had a localized disease and 24 pts had metastases in one site (n=14) or in multiple sites (n=10). The most frequent metastatic sites were lung (n=9), liver (n=7), bone (n=7), brain (n=4). Tumors were mainly located in the atrial cavities (right atrium n=47; left atrium n=44). Other localization included right ventricle (n= 6), left ventricle (n=9) and pericardium (n=3). In 11 cases, the tumor was multifocal. A surgical approach was considered in the majority of pts with localized disease. Resection alone or in combination with doxorubicin-containing chemotherapy (CT) or with a radiotherapy and CT regimen was undertaken in 18, 43 and 16 pts respectively. Among these pts, surgical approaches included wide excision (n=10), marginal excision (n=22), intralesional excision (n=31) and heart transplant (n=5). The median follow up was 13 mo (0-153), the median overall survival (OS) for those who underwent R0 excision was 39 mo (range 8-96) versus 17 mo (range 0-153) for those with R1 or R2 resection. The median OS of pts with initial metastatic disease treated with doxorubicin-containing CT was 11 mo (range 2-95). Conclusions: Complete surgical excision is associated with long-term survival. However, the poor prognosis of this malignancy requires extensive multidisciplinary research studies.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10071
Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.
10071 Background: Data regarding the role of systemic therapy in patients (pts) with advanced well-differentiated/dedifferentiated liposarcomas (WLPS/DDLPS) are limited. Methods: From 2000 to 2010, 166 pts with a confirmed diagnosis of WDLPS/DDLPS were referred to one of the 8 participating institutions, and their medical records reviewed. Results: Median age was 63 years (range 34-84). Thirty pts had WDLPS and 136 pts had DDLPS. Primary tumor sites were: retroperitoneum n=120 (73%), limb n=19 (11%), other n=27 (16%). 111 pts (67%) had metastatic disease (peritoneal sarcomatosis n=75; lung n=30, liver n=19, bone n=5) and 55 pts (33%) had locoregional unresectable disease. 27 pts (16%) had ≥ 2 metastatic sites. 103 pts (62%) received 1st line single agent chemotherapy. 131 pts (79%) received a 1st line anthracycline-containing regimen (doxorubicin n=64, doxorubicin + ifosfamide and/or dacarbazine: n=45, other: n=22). Non-anthracycline regimens were: metronomic cyclophosphamide or etoposide: n=17; trabectedin: n=4, others: n=14. RECIST objective response was observed in 18 pts (11%), all treated with anthracyclines. Response rate was higher in pts receiving combination chemotherapy: 17% vs 7%, p=0.03. 62 pts (37%) had stable disease > 6 months. Median progression-free survival (PFS) was 5.2 months (95% CI: 3.4-7.0). On multivariate analysis, performance status (PS) ≥ 2 was the sole factor significantly associated with poor PFS (Hazard ratio [HR]= 2.2; 95% CI 1.4–3.5; p3 (HR= 2.2; 95% CI 1.2–3.9; p = 0.01) were the sole factors significantly associated with poor OS. Conclusions: Chemotherapy is associated with a non-progression rate of about 50% in pts with advanced WDLPS/DDLPS. Combination chemotherapy gives higher response rate than single agent but appears to have no impact on PFS or OS. OS of pts with advanced WDLPS/DDLPS is poor, even if visceral metastatic disease is less frequent than in other sarcomas. Best supportive care should be considered in pts with poor PS.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10071
Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.
10071 Background: Data regarding the role of systemic therapy in patients (pts) with advanced well-differentiated/dedifferentiated liposarcomas (WLPS/DDLPS) are limited. Methods: From 2000 to 2010, 166 pts with a confirmed diagnosis of WDLPS/DDLPS were referred to one of the 8 participating institutions, and their medical records reviewed. Results: Median age was 63 years (range 34-84). Thirty pts had WDLPS and 136 pts had DDLPS. Primary tumor sites were: retroperitoneum n=120 (73%), limb n=19 (11%), other n=27 (16%). 111 pts (67%) had metastatic disease (peritoneal sarcomatosis n=75; lung n=30, liver n=19, bone n=5) and 55 pts (33%) had locoregional unresectable disease. 27 pts (16%) had ≥ 2 metastatic sites. 103 pts (62%) received 1st line single agent chemotherapy. 131 pts (79%) received a 1st line anthracycline-containing regimen (doxorubicin n=64, doxorubicin + ifosfamide and/or dacarbazine: n=45, other: n=22). Non-anthracycline regimens were: metronomic cyclophosphamide or etoposide: n=17; trabectedin: n=4, others: n=14. RECIST objective response was observed in 18 pts (11%), all treated with anthracyclines. Response rate was higher in pts receiving combination chemotherapy: 17% vs 7%, p=0.03. 62 pts (37%) had stable disease > 6 months. Median progression-free survival (PFS) was 5.2 months (95% CI: 3.4-7.0). On multivariate analysis, performance status (PS) ≥ 2 was the sole factor significantly associated with poor PFS (Hazard ratio [HR]= 2.2; 95% CI 1.4–3.5; p3 (HR= 2.2; 95% CI 1.2–3.9; p = 0.01) were the sole factors significantly associated with poor OS. Conclusions: Chemotherapy is associated with a non-progression rate of about 50% in pts with advanced WDLPS/DDLPS. Combination chemotherapy gives higher response rate than single agent but appears to have no impact on PFS or OS. OS of pts with advanced WDLPS/DDLPS is poor, even if visceral metastatic disease is less frequent than in other sarcomas. Best supportive care should be considered in pts with poor PS.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10070
Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO).
10070 Background: Five-year overall survival (OS) of localized RMS of children < 18 exceeds 70%, while OS in adult pts is poor. We report a retrospective experience from centers of GSF-GETO. Methods: From May 1981 to February 2010,157 adult pts (≥18 yrs) treated in 13 centers were analyzed. OS was determined using Kaplan-Meier method and analyzed with the logrank test and Cox model. Results: At diagnosis, 111 pts had localized RMS without lymph nodes (N) and/or (+/-) metastases (M). There were 100 males and 57 females (median age: 37 yrs, range 18-86). Histologic subtypes were embryonal (E) (21%), alveolar (A) (35%) and pleomorphic (P) (44%). Primary tumor site were limbs (48%), head and neck (25%), genitourinary (9%) and others (18%). Median tumor size was 8 cm (range 1-56). E, A, and P RMS were located in the limbs (18% vs 33% vs 75% p=0.001), with a median age of 25 vs 26 vs 51 yrs respectively (p=0.001) and N +/- M (21% vs 53% vs 14% p=0.001). 125 pts received chemotherapy (CT) including 81/111 with localized RMS. RMS subtype influenced clinical management, adjuvant CT (58% for P and 92% for E/A RMS), administration of pediatric protocols (PP) (14% for P and 62% for E/A RMS) (p<0.001). Surgery was performed in 108/157 (69%) pts with R0, R1 or R2 margins in 60%, 28% and 10% respectively among 96 evaluable pts. 107 pts (81 with localized RMS) received radiotherapy (RT). With a median follow up of 8.5 yrs, 5-yrs OS for localized RMS and advanced RMS were 43% and 5% (p<0.0001) and 52%, 20%, 46% for E, A and P localized RMS respectively (p=0,2). In multivariate analysis, for localized RMS, A RMS (p<0.001), age (p=0.001), sex (male) (p=0,045), R0 resection (p<0.001), RT (p<0.001) and PP (p=0,002) influenced OS. For RMS with N +/- M, age (p=0,062), sex (p=0.068), R0 resection (p=0.015), RT (p=0.085) influenced OS. Conclusions: Outcome of pts remains poor for all subtype RMS, E/A RMS compared to childhood RMS and P RMS compared to STS in adult pts.Surgery allows better outcome for all patients. Respect of PP for localized RMS should be preferred.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10070
Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO).
10070 Background: Five-year overall survival (OS) of localized RMS of children < 18 exceeds 70%, while OS in adult pts is poor. We report a retrospective experience from centers of GSF-GETO. Methods: From May 1981 to February 2010,157 adult pts (≥18 yrs) treated in 13 centers were analyzed. OS was determined using Kaplan-Meier method and analyzed with the logrank test and Cox model. Results: At diagnosis, 111 pts had localized RMS without lymph nodes (N) and/or (+/-) metastases (M). There were 100 males and 57 females (median age: 37 yrs, range 18-86). Histologic subtypes were embryonal (E) (21%), alveolar (A) (35%) and pleomorphic (P) (44%). Primary tumor site were limbs (48%), head and neck (25%), genitourinary (9%) and others (18%). Median tumor size was 8 cm (range 1-56). E, A, and P RMS were located in the limbs (18% vs 33% vs 75% p=0.001), with a median age of 25 vs 26 vs 51 yrs respectively (p=0.001) and N +/- M (21% vs 53% vs 14% p=0.001). 125 pts received chemotherapy (CT) including 81/111 with localized RMS. RMS subtype influenced clinical management, adjuvant CT (58% for P and 92% for E/A RMS), administration of pediatric protocols (PP) (14% for P and 62% for E/A RMS) (p<0.001). Surgery was performed in 108/157 (69%) pts with R0, R1 or R2 margins in 60%, 28% and 10% respectively among 96 evaluable pts. 107 pts (81 with localized RMS) received radiotherapy (RT). With a median follow up of 8.5 yrs, 5-yrs OS for localized RMS and advanced RMS were 43% and 5% (p<0.0001) and 52%, 20%, 46% for E, A and P localized RMS respectively (p=0,2). In multivariate analysis, for localized RMS, A RMS (p<0.001), age (p=0.001), sex (male) (p=0,045), R0 resection (p<0.001), RT (p<0.001) and PP (p=0,002) influenced OS. For RMS with N +/- M, age (p=0,062), sex (p=0.068), R0 resection (p=0.015), RT (p=0.085) influenced OS. Conclusions: Outcome of pts remains poor for all subtype RMS, E/A RMS compared to childhood RMS and P RMS compared to STS in adult pts.Surgery allows better outcome for all patients. Respect of PP for localized RMS should be preferred.